In pursuit of its human health care philosophy, Eisai China Inc. strives to maintain the highest GMP standard in manufacturing products and strictly adheres to the highest level of ethics and compliance. Through this commitment, Eisai China Inc not only provides high-quality, eco-friendly, safe and satisfactory products and services to patients and their families, but also proactively contribute to society by supporting programs and activities that help promote the advancement of medical sciences (e.g. “Eisai Scholarship Award”), increase awareness about diseases (e.g. “Yellow Handkerchief Love Action”), and provide aide in times of disasters.
The OSD of Suzhou Plant won the Suzhou City-level Model Intelligent Workshop.
On World Alzheimer’s Day, Eisai has released a dementia awareness video, “Life Goes On 2023: Two Memories, One Story” globally.
Alzheimer’s Disease Handbook 2023 released.
“Le-Guan-Xiang-Qian”–Patient Assistance Program for Liver Cancer in County Areas is launched.
Eisai China and Shanghai Yinfatong Internet Hospital (a subsidiary of Unlimit Health Limited) launched the “Memory and Love” – A Brain Health Care Program for the Elderly.
Eisai China Calls for “Concern for Brain Health, Early Detection, Early Diagnosis, Early Intervention” at the “2023China Brain Health Conference.”
Suzhou plant successfully completed the 2022 greenhouse gas and product carbon foot-printing.
Suzhou plant successfully passed the energy management system certification.
Eisai China Scholarship Award Ceremony was successfully held at School of Business Administration, Shenyang Pharmaceutical University.
The “Hai-Yun-Xin-Sheng” breast cancer PAP
In order to help more patients diagnosed with breast cancer to receive timely and effective treatment, reduce their financial burden and prolong their lives, the China Primary Health Care Foundation launched the “Hai-Yun-Xin-Sheng” Breast Cancer Patient Assistance Project (PAP) in September 2020, and Eisai provided free drug Halaven to the China Primary Health Care Foundation. As of March 2023, there are 207 low-insurance patients and 2,204 low-income patients with 25,687 injection for a cumulative donation value of RMB 102.2 million.
In order to help more patients diagnosed with hepatocellular carcinoma to receive timely and effective treatment, reduce their financial burden and prolong their lives, China Charity Federation launched the “Wei-Ai-Xin-Sheng” Patient Assistance Project (PAP) in December 2022, and Eisai provided free Levima to China Charity Federation, which aims to help patients with hepatocellular carcinoma to receive more durable and effective medical treatment and improve their quality of life.
Top Employer China 2023